References
- Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. Ophthalmology 1989; 96(2): 255–64
- Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care 2002; 25(3): 476–81
- Bresnick GH, Mukamel DB, Dickinson JC, et al. A screening approach to the surveillance of patients with diabetes for the presence of vision-threatening retinopathy. Ophthalmology 2000; 107(1): 19–24
- Ferris FL 3rd, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med 1999; 341(9): 667–78
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 29(14): 977–86
- Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105(10): 1801–15
- Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003; 136(1): 122–35
- Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351(9095): 28–31
- Chaturvedi N. Modulation of the renin-angiotensin system and retinopathy. Heart 2000; 84(Suppl 1): i29–31
- Chew EY, Klein ML, Ferris FL 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996; 114(9): 1079–84